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Abstract
Background: We sought to determine whether clinical response or tolerance to the Selective Serotonin Reuptake Inhibitor
(SSRI) citalopram is associated with genetic polymorphisms in potentially relevant pharmacokinetic enzymes.
Methodology: We used a two-stage case-control study design in which we split the sample of 1,953 subjects from the
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial into a discovery (n=831) and validation set
(n=1,046). Fifteen polymorphisms from five (CYP2D6, ABCB1, CYP2C19, CYP3A4, and CYP3A5) pharmacokinetic genes were
genotyped. We examined the associations between these polymorphisms and citalopram response and tolerance.
Significant associations were validated in the second stage for those polymorphism found to be statistically significant in
the first stage.
Conclusions: No genetic polymorphism in the pharmacokinetic genes examined was significantly associated with our
response or tolerance phenotypes in both stages. For managing pharmacological treatment with citalopram, routine
screening of the common pharmacokinetic DNA variants that we examined appears to be of limited clinical utility.
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Introduction
Significant inter-individual variation exists in clinical response
to and tolerance of antidepressant medication. Common genetic
variation may be partly responsible for these phenotypic
differences. The use of genotype information in clinical psycho-
pharmacology could potentially help clinicians avoid the standard
trial and error approach, and allow a more efficient way to
maximize efficacy and minimize toxicity [1–3] as is done in certain
situations with cancer treatment [4].
Drug metabolism and transport genes such as CYP2D6 and
CYP2C19 are obvious pharmacogenetic candidate genes given
their known interaction with drugs like selective serotonin
reuptake inhibitors (SSRI) and their metabolites in vivo [5].
Moreover, several of these pharmacokinetic genes harbor common
variants that have been shown to impair enzyme function [6]. For
example, Yin et al. found that homozygous carriers of the non-
functional allele of CYP2C19 show a 42% decrease in clearance of
the SSRI citalopram compared to that of homozygous carriers of
the wild type allele [7]. Gra ¨smader et al. showed that plasma
concentrations of several antidepressants were significantly
influenced by CYP2D6 and CYP2C19 genotype, however, clinical
response was not associated with plasma concentrations of these
drugs [8].
Despite these known in vivo relationship between antidepressant
medications and pharmacogenetic genes, few epidemiological
studies investigating the relationship between antidepressant
response and pharmacokinetic gene variants have been carried
out. In a naturalistic, retrospective study of 28 patients who
experienced adverse events and 16 patients that were non-
responsive to a variety of antidepressants, the authors observed an
association with CYP2D6 genotype [9]. In a prospective study of
246 elderly subjects taking the SSRI paroxetine, CYP2D6
genotype was not associated with side effect burden [10]. Another
recent study of 100 depressed subjects taking fluvoxamine showed
that CYP2D6 genotype does not influence the frequency of
gastrointestinal side effects, although when CYP2D6 genotype is
combined with a serotonin 2A receptor polymorphism, the
authors did observe such an association [11]. Despite the
equivocal results of these studies, some investigators have
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to guide clinical therapy of SSRI, particularly by adjustment of the
dose prescribed [12,13]. Even though there is intuitive appeal in
ascribing differences in drug tolerance and efficacy to variation in
pharmacokinetic genes [13,14] no adequately powered studies
have been published that consistently report a significant clinical
effect. Here, we investigate the potential role of five pharmaco-
kinetic genes on the response to and tolerance of citalopram using
a large clinical sample of depressed patients who were enrolled in
the Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study [15].
Materials and Methods
Sample
Subjects are those who enrolled in STAR*D and consented to
give DNA (N=1,953). The STAR*D trial was a large NIMH-
sponsored treatment trial involving 4,041 subjects that was
designed to assess effectiveness of antidepressant treatments in
generalizable samples, and to determine outcomes for outpatients
with non-psychotic major depressive disorder (MDD) treated with
citalopram. The study design and methods for this clinical trial are
reviewed in [16], and further demographic information on the
cohort that consented to give DNA has been previously published
[17]. The aim of STAR*D was to prospectively determine which
of a number of treatments are beneficial for subjects experiencing
an unsatisfactory response to citalopram. To increase the
generalizability of the findings, STAR*D utilized broad inclusion
criteria and enrolled an ethnically diverse population [15].
Diagnosis was made using the Psychiatric Diagnostic Screening
Questionnaire, and depressive symptoms were assessed with the
16-item Quick Inventory of Depressive Symptomatology (Self-
Report [QIDS-SR] version) [18] collected at baseline and at all
clinic visits. Subjects meeting inclusion criteria and providing
consent were administered citalopram for a target trial of 12 weeks
of treatment with vigorous dosing (20–60 mg/day). The subset of
subjects who provided DNA samples was 61.8% female and was
78.1% Caucasian, 16.1% African-American, and 5.8% other races
[19]. Hispanics accounted for 14.0% of the sample. The average
citalopram dose at study exit was 45.5 mg (S.D.=15.7). Subjects
were consented for genetic studies as part of the National Institute
of Mental Health’s Human Genetic Initiative and the work
described here was approved by the institutional review board of
the University of California, San Francisco.
Phenotypic definitions
We defined six phenotypes to evaluate citalopram response and
tolerability. The first two were responders and non-respond-
ers: responders are subjects who had at least 42 days of treatment
and whose QIDS-SR score on their final clinical visit shows $50%
reduction in score compared to baseline; the remaining subjects,
who also had at least 42 days of treatment, were then considered
non-responders. The $50% reduction in symptom severity on the
HRSD17 is the conventional definition of response in clinical trials.
We used the QIDS-SR score to estimate severity since all subjects
had this rating and it correlates highly with the 17-item Hamilton
Rating Scale for Depression (HRSD17) score [18]. We required
this 42 day threshold to ensure an adequate exposure to
citalopram and to enhance the power to find associations between
genotype and response by reducing potential heterogeneity. The
third phenotype was remission, defined as a final QIDS-SR
score #5. Our specific response phenotype is based on our
attempt to further reduce heterogeneity by attempting to separate
placebo response from true drug response in antidepressant trials
[20]. Some response to antidepressant medication is a placebo
response, which we posit may have either no genetic determinant
or a different genetic substrate than ‘‘true’’ drug response. Thus it
is of interest to limit our definition of response to true
pharmacologic response rather than placebo response. For these
phenotypes, a ‘‘specific’’ pattern of response was defined by
persistence, or the maintenance of response for the remainder of
the study once it was attained. Previous studies considered
‘‘specific’’ patterns to be further characterized by delayed
response, i.e., after the first two weeks [21]. We were unable to
employ this criterion because the STAR*D study design did not
include ratings before week two of treatment, except for baseline
scores. We defined persistent, or ‘‘specific’’ responders, as those
subjects who had a sustained response at all consecutive visits
following the first visit with response, as measured by $50%
reduction in QIDS-SR scores. Those whose response occurred
only at the last visit were removed from the analysis. Note that
‘‘specific’’ responders are a subset of responders (as defined by the
response phenotype above). Moreover, because visits were at least
two weeks apart, we assumed that intervening weeks were
characterized by the response defined by the previous visit. Our
tolerance outcome was based on study exit data; all patients who
continued with citalopram at the end of STAR*D Level 1
treatment were considered tolerant, while patients who refused
to continue citalopram or left the study at any time due to side
effects were considered intolerant. For those who left Level 1 for
further treatment but did not want to continue with citalopram,
their phenotype was probably tolerant, probably intolerant, or
intolerant based on the level of side effects at the study exit based
on the Global Rating of Side Effect Burden [22]. In order to
reduce heterogeneity, we did not use subjects who were considered
probably tolerant or probably intolerant. The mean duration of
treatment was 11.10 weeks for non-responders, 12.42 weeks for
responders, and 12.39 weeks for remitters. For the tolerance
phenotype, the mean duration was 6.62 weeks for intolerant
subjects and 12.14 weeks for tolerant subjects.
Molecular methods
Several cytochrome P450 genes (CYP2C19, CYP2D6,
CYP3A4, CYP3A5) are thought to be involved in the metabolism
of citalopram [23]. We chose to examine DNA variants in
cytochrome P450 genes that cause or are suspected to cause severe
functional changes in the targeted proteins. However, for CYP3A
enzyme activity, there are no known functional polymorphisms,
thus we investigated two common SNPs in these genes. Indeed,
CYP3A enzyme activity may play a small role in citalopram
pharmacokinetics, as co-administration of the CYP3A inhibitor
ritonavir does not substantially alter citalopram pharmacokinetics
[24]. While citalopram is lipophilic and can cross the blood brain
barrier without transport to some degree, the transporter P-
glycoprotein (ABCB1) has been shown in animal models to
contribute to the efflux of citalopram from the brain [25].
Therefore, we investigated three common SNPs in the ABCB1
gene (C1236T, G2677T, and C3435T) that have been associated
with treatment outcome in acute myeloid leukemia patients and
reduced P-glycoprotein expression in vivo [26,27]. Due to the low
population frequency of the more recently described G2677A
allele (,2% in Caucasians), this variant was not genotyped in the
present study [28].
Patients were genotyped for CYP3A5*3C, all three CYP2C19
variants (*2, *3, *17), and all three MDR1 variants using 59
exonuclease fluorescence (Taqman) assays. CYP2D6*5 deletion
status was determined using a previously published tetra-primer
long range PCR assay [29]. All other CYP2D6 alleles (*3, *4, *6,
PK Genes and SSRI Sesponse
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CYP2D6 gene as a 5.1 kb long range PCR product (as described
in [29]) followed by direct sequencing of two regions containing
exons 3–4 and exons 5–6. This two step amplification procedure
was preformed in order to avoid non-specific amplification of the
CYP2D6 pseudogene located near the CYP2D6 gene. CY-
P3A4*1B genotype was determined by direct sequencing of a
320 bp PCR product that specifically amplifies the 59 proximal
region of the CYP3A4 gene [30]. PCR protocols and primer
sequences are available upon request, and a synopsis of the 15
variants is shown in Table S1. Direct sequencing genotypes were
scored using Mutation Surveyor v2.61. Genotype data has been
deposited with the NIMH Center for Collaborative Genetic
Studies on Mental Disorders (http://nimhgenetics.org/).
Statistical methods
To reduce Type I error, we relied on a two-stage design for
analysis [31]. Within each ethnic group, gender, and response to
citalopram (using only our responders and nonresponders
phenotypes), we randomly split our subjects a priori into a
discovery set and validation set. Within each set, we stratified all
analyses by self-reported ethnicity due to the large allele frequency
differences and phenotype prevalence differences between ethnic
groups. Only the two largest ethnic groups (Caucasian and
African-American) were analyzed. Hardy-Weinberg equilibrium
was evaluated for each SNP within the discovery set using all
participants within each ethnic group. This is because all subjects
had depression, and we do not suspect the variants to influence
risk of depression. No SNPs were found to violate Hardy-
Weinberg equilibrium using a Bonferroni-corrected threshold. We
used unconditional logistic regression analysis to examine
associations between each genetic polymorphisms and each
phenotypic comparison. Comparisons performed were: 1) respond-
ers vs. non-responders,2 )remitters vs. non-responders,3 )specific responders
vs. non-responders, and 4) tolerant vs. intolerant. Each polymorphism
was modeled individually as gene-dosage effects in the regression
models, and odds ratios (OR) and 95% confidence intervals were
estimated. For the CYP2D6 and CYP2C19 genes, we also
modeled the putative metabolism status of the subjects as follows.
Individuals with two non-functional alleles in these genes were
considered poor metabolizers (PMs), all other genotypes were
considered extensive metabolizers (EM). Association between
haplotypes and the phenotypes were calculated using a score test
implemented in the computer program HAPLO.SCORE [32].
Pair-wise interactions among all independent SNPs were tested
using logistic regression. A likelihood ratio test was used to test for
significance of the interaction effect. Only those SNPs with a p-
value of ,0.05 from the single SNP analyses in the discovery set
were evaluated in the validation set. Those SNPs in the validation
set that had a p-value ,0.05 and the same directionality of
association as that in the screening set were reported as statistically
significant. We used survival analysis to examine whether
metabolizer status influenced the ability to complete the trial.
Survival curves were generated by the method of Kaplan-Meier,
and differences between PM and EM curves were tested using the
log rank statistic. We also examined the relationship between
metabolizer status and citalopram dose, comparing final dose
between extensive and poor metabolizers at the CYP2D6 and
CYP2C19 loci with a t-test. No correction for multiple
comparisons was applied to our association tests. The two-stage
design helps to control Type I error by requiring nominal
statistical significance in both stages to be ultimately declared
significant. The probability of a variant being significant at the
0.05 level in both stages is expected to be low.
Results
Patients were genotyped for 15 polymorphisms in the CYP2D6,
CYP2C19, CYP3A4, CYP3A5, and ABCB1 genes. We compared
genotype frequencies between responders and non-responders,
remitters and non-responders, and specific responders and non-
responders within each racial subgroup. Note that remitters and
specific responders are subsets of responders. We also compared
genotype frequencies of subjects intolerant to citalopram to those
who could tolerant the medication. Table 1 displays the frequency
distribution of the phenotypes by ethnicity among subjects for the
discovery and validation sets. Because one of our criteria for
splitting our sample was based on the response/non-response
phenotypes, the distribution of response and non-response are
similar between the discovery and validation set. In the discovery
set, we found seven variants to be associated (p,0.05) with
citalopram response or tolerance. All but one of these were found
in the African-American ethnic group. However, none of these
SNPs were replicated in our validation set (Table 2). It is of note
that the point estimates for the odds ratios for nearly all of these
variants switched directionality in the second stage, most likely as a
Table 1. Sample sizes of the discovery and validation subsets for each racial subgroup.
Variable Discovery Set Validation Set
Pheno 1
a Pheno 2
b Pheno 3
c Pheno 4
d Pheno 1
a Pheno 2
b Pheno 3
c Pheno 4
d
Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No
N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%)
Ethnicity
African-American 66 63 52 63 40 63 89 9 64 58 48 58 37 58 86 13
(51.2) (48.8) (45.2) (54.8) (38.8) (61.2) (90.8) (9.2) (52.5) (47.5) (45.3) (54.7) (39.0) (61.0) (86.9) (13.1)
Caucasian 395 257 331 257 287 257 514 51 404 254 348 254 272 254 554 125
(60.6) (39.4) (56.3) (43.7) (52.8) (47.2) (91.0) (9.0) (61.4) (38.6) (57.8) (42.2) (51.7) (48.3) (81.6) (18.4)
a,Responder vs. Non-Responder
b,Remitter vs. Non-Responder
c,Specific Responder vs. Non-Responder
d,Tolerant vs. Intolerant
doi:10.1371/journal.pone.0001872.t001
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variants. Similar non-significant results were obtained using
haplotype testing (results not shown). CYP2D6 or CYP2C19
metabolizer status (PM vs. EM) was also not associated with
citalopram response or tolerance in the first stage (results not
shown). We also found no evidence for interaction (P.0.05)
between the variants in any of the genes tested (results not shown).
We further sought to determine if metabolizer genotype was
correlated with other clinical variables of interest, namely the
dosage of citalopram and the length of time a subject would
continue with citalopram treatment. For all subjects, regardless of
outcome or length of trial, dose was not correlated with CYP2D6
or CYP2C19 metabolizer status (see Table 3). Additionally,
CYP2C19 or CYP2D6 metabolizer status did not significantly
influence the subject’s ability to remain in the trial (P=0.65 and
P=0.95, respectively).
Discussion
There is growing interest in the utility of pharmacokinetic gene
polymorphism screening in psychopharmacological treatment,
particularly with antipsychotic medications and older antidepres-
sant agents [6]. Others have argued that the efficacy and toxicity
of most psychotropics could be influenced by DNA variants in
pharmacokinetic genes, and that drug selection and dosage should
ideally be based on genotypic information [12,13]. There is
growing consensus that there is little data that suggests that
assessment of cytochrome P450 polymorphisms may be clinically
useful for guiding SSRI therapy [33].
The flat dose-response curve and wide therapeutic index of
SSRIs argue against a strong relationship between plasma levels
and clinical response [34] and there is little evidence regarding
how plasma levels of citalopram influence clinical efficacy [35].
This appears to be the case for citalopram, which has few drug-
drug interactions based on in vitro and in vivo studies [23].
Nevertheless, the pharmacokinetics of many SSRIs, including
citalopram, are affected by CYP2D6 and CYP2C19 genotype
status, as polymorphisms in these enzymes do alter citalopram
disposition [7,36–38]. For example, CYP2C19 poor metabolizers
showed a 42% decrease in citalopram clearance when compared
to homozygous extensive metabolizers, yet there was no difference
in the subject’s side effect profile [7]. In another study of seven
non-responders to citalopram, six of seven were extensive
metabolizers for CYP2D6 and all seven were CYP2C19 extensive
metabolizers [39]. When given an inhibitor of these two enzymes,
citalopram serum levels rose in all seven subjects, with six of them
showing substantial clinical improvement. These data suggest that
enzymes involved in citalopram metabolism may contribute to
response, at least in some extensive metabolizers. There are no
similar data regarding side effects, although a large (n=749)
Swedish study found no difference in citalopram or desmethylci-
talopram levels between those experiencing a number of common
side effects compared and those who did not, suggesting that side
effects are influenced primarily by pharmacodynamic rather than
pharmacokinetic factors [40]. A study by Murphy et al. also found
pharmacodynamic gene variation to be important in antidepres-
sant intolerance [10]. Recently, a study was reported involving
genotyping of ABCB1 variants in persons taking antidepressants in
which an association between several of these variants and
response in ,114 persons taking ABCB1 substrates, but not in
,85 persons taking drugs that are not substrates for the protein
encoded by ABCB1 [41]. The three ABCB1 variants that we
genotyped for this report were genotyped by Uhr et al., and just as
in our study, no association with response phenotypes were noted.
For the eleven SNPs found to be associated by Uhr et al., ten are
in very strong linkage disequilibrium. Three of these markers were
genotyped as part of our unpublished genome-wide association
study of antidepressant response in our sample, and these three
adequately tag the ten correlated markers based on CEU HapMap
Phase II data (r
2$0.8 or=1.0 for seven or five of seven remaining
markers, respectively). These three markers, rs10280101,
rs2235040, and rs12720067, showed p-values of 0.58, 0.30, and
0.56, respectively, for the remission phenotype. Urh et al. reported
one additional marker as being associated with antidepressant
response. This marker, rs2235015, was not genotyped by us, nor
Table 2. Single locus results for tests that were significant (p,0.05) in the discovery sample set.
Ethnicity Phenotypic Comparison Gene Variant
Discovery set p-value (OR,
95% CI)
Validation set p-value (OR,
95% CI)
Caucasian Tolerant vs. Intolerant CYP2C19 *2 0.005 (0.44, 0.24–0.81) 0.86 (1.00, 0.63–1.57)
African-American Responder vs. Non-Responder ABCB1 C3435T 0.01 (0.36, 0.17–0.75) 0.59 (1.51, 0.70–3.26)
African-American Remitter vs. Non-Responder ABCB1 C3435T 0.02 (0.36, 0.16–0.78) 0.85 (1.28, 0.56–2.93)
African-American Specific Responder vs Non-Responder CYP2D6 *5 0.03 (4.44, 1.07–18.39) 0.32 (0.45, 0.09–2.37)
African-American Specific Responder vs Non-Responder CYP2D6 *4 0.04 (0.26, 0.05–1.23) 0.96 (1.24, 0.35–4.41)
African-American Specific Responder vs Non-Responder ABCB1 C3435T 0.02 (0.40, 0.17–0.93) 0.71 (1.39, 0.58–3.35)
African-American Tolerant vs. Intolerant CYP3A5 *3 0.04 (0.32, 0.08–1.37) 0.33 (1.57, 0.48–5.07)
Significance was assessed using logistic regression, and odds ratios (OR) and confidence intervals (CI) shown are for minor allele carrier versus non-carrier. No variants
were significantly associated in both the discovery and validation sample sets.
doi:10.1371/journal.pone.0001872.t002
Table 3. Effect of subject metabolizer status on final
citalopram dose.
Metabolizer Status Mean Final Dose (s.d.) p-value
CYP2C19 EM 45.3 (15.7) 0.13
CYP2C19 PM 40.7 (16.4)
CYP2D6 EM 45.4 (15.8) 0.25
CYP2D6 PM 43.2 (16.8)
Mean final dose (mg) for each metabolizer group is shown, along with the
standard deviation (S.D.) and significance level assessed using student’s t-test.
Results are shown for the Caucasian subgroup, similar non-significant results
were obtain in the African-American subset.
doi:10.1371/journal.pone.0001872.t003
PK Genes and SSRI Sesponse
PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e1872did we genotype a SNP tagging this marker. Thus it is an open
question if this last marker shows association to treatment response
phenotypes in our sample.
The size of the STAR*D study provides a clinical sample with
statistical power to detect moderately sized genetic influences. In
this study, we detected no significant association between any of
the polymorphisms and our treatment phenotypes. Our two-stage
analysis allowed us to control Type I error by requiring validation
of our results in a second sample. However, by splitting our sample
as such, we sacrificed statistical power, and thus increased the risk
of Type II error. For our response phenotype in the discovery set,
we had 80% power to detect a minimum detectable odds ratio of
1.9 assuming an allele frequency of 0.05 and 5% significance level
using our Caucasian sample. The minimum detectable odds ratio
increased to 2.74 for the tolerance phenotype. There are
multitudinous potential analyses that can be carried out given
the richness of the phenotypic data. In this study, we did not
formally correct our results for multiple comparisons, although our
two-stage design serves to control Type I error, lending further
support to the overall negative results. The availability of our
genotype data at the NIMH Center for Collaborative Genetic
Studies on Mental Disorders facilitates additional exploratory
hypothesis testing.
Our study has several limitations. Given the many differences in
SNP allele frequencies and phenotype classification among self-
reported ethnic groups, population stratification may be a
potential explanation for our negative findings, with true
associations being obscured by unobserved population sub-
structure. This is particularly relevant given the wide differences
in allele frequencies between populations for many of the genes
studied here [42]. However, population studies have found that
self-reported ethnicity is a close surrogate for underlying genetic
ancestry information [43], thus we sub-grouped our analyses based
on self-reported ethnicity in order to limit potential confounding.
By analyzing the ethnicity groups separately and using a two-stage
association approach, we had reduced power to detect associations
in the African American subgroup, and thus cannot entirely
dismiss these loci in this subgroup. We limited our genotyping of
pharmacokinetic candidate genes to known, deleterious alleles that
are common in Caucasian populations. In order to comprehen-
sively screen these genes, rare and functionally unknown variants
would need to be genotyped. The STAR*D clinical study, while
large and broad in scope, was not explicitly designed for
pharmacogenetic studies of this type. For instance, citalopram
was chosen partly due to its lower potential for influence by
pharmacokinetic polymorphism. Citalopram dosage was also not
fixed, though the majority of subjects (78%) were receiving 40–
60 mg per day at the end of the study. The final citalopram dosage
prescribed was not influenced by the subject’s genotype status.
This is consistent with work carried out with many of the same
functional DNA variants in the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) study, in which there was no
association to dosing, efficacy, or tolerability to five antipsychotics
(David Goldstein, personal communication). This observation is
particularly interesting in that others have noted a strong
correlation between maximum prescribed dose of phenytoin or
carbemazepine in epilepsy and genetic variants in CYP2C9 or
SCN1A , suggesting clinical adjustment of dose in response to
genotype [44]. Reflecting the ‘‘real-world’’ treatment focus of the
STAR*D study, patients were not drug naı ¨ve and certain
concomitant medications for general medical conditions were
allowed during treatment. Unfortunately, systematic data on
concomitant medications was not collected during the trial, and
thus we were unable to control for this theoretical drug-drug
interaction effect. It is noteworthy that the analysis of the CATIE
study indicates that using concomitant medications known to alter
metabolic status did not alter the results (David Goldstein,
personal communication). While clinical outcome, not alteration
of pharmacokintetic profiles, was our study endpoint, circulating
concentrations of citalopram or citalopram metabolites would
have been a useful proxy measure of compliance. Unfortunately,
plasma citalopram levels were not obtained from any STAR*D
subjects, thus unmeasured compliance is a limitation of this study
and consequently reduces our statistical power. The design of
genetics component of STAR*D was not entirely prospective, with
some subjects consenting for DNA collection any time after
initiating treatment, raising the possibility that those consenting for
genetic analysis do not represent all subjects. We adjusted our
analyses for the time period between starting the trial and donating
blood for DNA, and found no effect on the results (data not
shown). Finally, our findings regarding citalopram may not be
generalizable to other SSRI’s, each of which has a unique
metabolic disposition. Any broadly administered pharmacogenetic
test will have to tolerate similar limitations in order to be useful in
‘‘real-world’’ clinical settings. Thus, at least for citalopram, it may
be premature to advocate pharmacokinetic gene analysis for dose
adjustment or clinical decision making.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0001872.s001 (0.06 MB
DOC)
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